Clinical Trial Update: Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for the combination of Nanoxel and Herzuma in salivary duct carcinoma is in early phases with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Duct Carcinoma

Drugs mentioned

• HERZUMA (TRASTUZUMAB)
• Nanoxel (null)

Snippet

Sponsor: Samsung Medical Center | Conditions: Salivary Duct Carcinoma | Phase 2 | Status: UNKNOWN